Ivabradine Tablet, Film Coated
Product Images NDC 60687-862

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 60687-862). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5 mg Ivabradine Tablet Blister.jpg (5 mg Ivabradine Tablet Blister)

Ivabradine 5 mg film-coated tablet label printed in duplicates on a sheet by American Health Packaging. The label includes the product name, strength, dosage form, lot number 1234567, and a placeholder for expiration date. It features barcodes on the left and right edges.*

FDA Label Image

5 mg Ivabradine Tablets Carton.jpg (5 mg Ivabradine Tablets Carton)

Ivabradine 5 mg film-coated tablets label showing a package size of 30 tablets (3 blister packs of 10 each). The label includes the NDC 60687-862-21 and indicates it is for oral use. The labeler is American Health Packaging. The label also includes storage instructions and a QR code for medication guide and prescribing information.*

FDA Label Image

Figure 4 (Figure 4)

A forest plot comparing hazard ratios (HR) and 95% confidence intervals (CI) for Ivabradine versus placebo across multiple demographic and clinical subgroups including age, sex, race, cause of heart failure, weight, baseline heart rate, NYHA class, ejection fraction, beta blocker use, aldosterone antagonist use, diabetes history, and hypertension history. The X-axis ranges from 0.25 to 1.50, indicating whether Ivabradine or placebo is favored.*

FDA Label Image

Figure 2 (Ivabradinetabfig2)

A chart displaying fold changes and 90% confidence intervals of various drug interactions affecting ivabradine pharmacokinetics (Cmax and AUC). It categorizes drugs as strong CYP3A4 inhibitors (ketoconazole), moderate CYP3A4 inhibitors (diltiazem, verapamil, grapefruit juice), a CYP3A4 inducer (St. John's wort), and others (sildenafil, lacidipine, simvastatin, lansoprazole, omeprazole, warfarin). Recommendations range from contraindicated to no dose adjustment, shown as relative changes compared to ivabradine alone.*

FDA Label Image

Figure 3 (Ivabradinetabfig3)

A line graph comparing the proportion of patients with heart failure hospitalization or cardiovascular death over time (months) between Ivabradine and placebo groups. The x-axis represents time from randomization up to 36 months, and the y-axis shows the proportion percentage. A table below the graph lists the number of subjects at risk in each group at various time points.*

FDA Label Image

Chemical Structure (Ivabradinetabstructure)

Chemical structure of ivabradine hydrochloride, showing its molecular framework including methoxy groups and a bicyclic ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.